Hemideina has raised funds via a private placement

Hemideina has raised US$7.4 million. The capital raised will be used to fund product development in preparation for the first human studies.

Hemideina is a Melbourne-based private company that is set to disrupt the cochlear implant market through its proprietary mechanical signal processing technology, the Hera wireless implant system. The company aims to provide a paradigm shift in hearing implant performance that will lead to increased access and adoption of treatment.

Oaklins’ team in Australia acted as lead manager in this transaction. The team has assisted Hemideina with fundraising since 2018 and is proud to support them on their mission to positively impact the lives of people with severe-to-profound hearing loss.

Servicio

Financiamiento, asesoramiento sobre la deuda y mercado de acciones

Partes

“I’d like to extend my thanks to the team for managing the raise, as well as our team. The high-caliber work completed to date has built confidence around our technology with investors and continues to be the key to our success.”

Elizabeth Williams

CEO and co-founder, Hemideina

Contáctese con el equipo de la transacción

Jonathan Tooth

Director

Melbourne, Australia
Oaklins Henslow

Ver perfil Ponte en contacto

Ryan Whitelegg

Director Ejecutivo

Melbourne, Australia
Oaklins Henslow

Ver perfil Ponte en contacto

Transacciones relacionadas

Den Berk Délice accelerates growth through strategic partnership

Private Equity | Agricultura

Den Berk Délice accelerates growth through strategic partnership

Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.

Conozca más

Xiel Limited has been acquired by MIS Healthcare

Private Equity | Salud

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Conozca más

Microfinanciera Fundeser has been sold to Grupo Financiero Atlántida

Private Equity | Servicios Financieros

Microfinanciera Fundeser has been sold to Grupo Financiero Atlántida

Incofin has successfully exited its investment in Microfinanciera Fundeser in Nicaragua through two of its funds: Rural Impulse Fund II (RIF II) and agRIF. It has sold 100% of its stake in Microfinanciera Fundeser to Grupo Financiero Atlántida through its subsidiary, Inversiones Tres Lagos.

Conozca más